Pfizer, who once ruled the cardiac drug scene with Lipitor and Norvasc, is pulling out of heart medications to focus on more profitable areas like oncology and Alzheimer’s disease.
They got burned pretty badly with the HDL-raising drug torcetrapib, and their combo statin-hypertension medication Caduet is having anemic sales.
Profits obviously dictate where innovation should lie. The same thing happened to antibiotics where there hasn’t been a breakthrough drug in years.
Related posts:
- Peter Rost piles on Pfizer
- Generics are killing Pfizer
- Combo drugs
- Desperate Pfizer going with ads to save failing Exubera
- How Pfizer plans to increase revenue
- Pfizer: Going to the dogs
- Bloodbath at Pfizer
KevinMD.com on Facebook
Comments on this entry are closed.